(Finance) – DiaSorinan Italian multinational active in the field of diagnostics and included in the FTSE MIB, closed the first quarter of 2022 with revenues equal to 358 million euros, an increase of 34.1% (+ 28% at constant exchange rates) compared to that recorded in the first quarter of 2021. immunodiagnostics ex-Covid grew by 10.1% (+ 6.6% at constant exchange rates), while revenues from molecular diagnostics ex-Covid recorded growth of 137.6% (+ 123.5% at constant exchange rates), mainly driven by the inclusion of the Luminex business (which contributed 97 million euros overall in the quarter) within the consolidation perimeter. Revenues licensed technologies amounted to 55 million euros. Sales of the tests serological and molecular for Covidequal to 97 million euros, decreased by 5.2% (-9.8% at constant exchange rates) compared to the same period last year.
L’Adjusted EBITDA was equal to 150 million euros, + 15.5% (+ 10.4% at constant exchange rates) compared to the figure recorded in the first quarter of 2021, with an incidence on revenues of 41.9% (48, 6% in the 1st quarter of 2021). L’Adjusted net profit was equal to 96 million euro (+ 10.6%), while the net profit was equal to 82 million (+ 5.2%). L’net financial debt settled at -860 million euros (-986 million at 31 December 2021), while the free cash flow was 116 million euros (80 million in the first quarter of 2021).
DiaSorin, which does not foresee material negative impacts resulting from the military conflict between Ukraine and Russia because it is not significantly exposed in these areas, has revised its guidance upwards for the year 2022 both in terms of revenues and margins, following a better trend in sales of Covid tests due to the Omicron variant. Revenues should show a trend of between -2% and + 1%, compared to that recorded in 2021, of which revenues relating to Covid products for approximately 150-180 million euros and ex-Covid revenues up by approximately 24%. The adjusted EBITDA margin should be between 35% and 37%.